Big Readouts For AstraZeneca, Daiichi Sankyo And Gilead At Lung Cancer Congress
Data At WCLC From Tagrisso And A Host Of ADCs
AstraZeneca’s Tagrisso could consolidate its place in EGFR-positive lung cancer, while Daiichi looks to go it alone with its own antibody-drug conjugate.
